<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etonogestrel implant: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etonogestrel implant: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Etonogestrel implant: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11732" href="/d/html/11732.html" rel="external">see "Etonogestrel implant: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="127394" href="/d/html/127394.html" rel="external">see "Etonogestrel implant: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3325519"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nexplanon</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54870318"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nexplanon</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3325522"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Contraceptive;</li>
<li>
                        Progestin</li></ul></div>
<div class="block doa drugH1Div" id="F3325912"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception: Subdermal:</b> Insert 1 implant in the inner side of the upper, nondominant arm. Remove no later than 3 years after the date of insertion; may be replaced with a new implant at the time of removal if continued contraceptive protection is desired. After ruling out pregnancy, timing of insertion is based on the patient's contraceptive history:</p>
<p style="text-indent:-2em;margin-left:4em;">Patients not currently using a hormonal contraceptive: Insert between days 1 through 5 of menstruation, even if the patient is still bleeding. A barrier method of contraception should be used for the first 7 days after insertion if deviating from the recommended timing of insertion. If intercourse has already occurred, pregnancy should be excluded.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Patients Switching to Etonogestrel from Another Contraceptive Method<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Current method</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Instructions for switching to etonogestrel</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<sup>a </sup>A barrier method of contraception should be used for the first 7 days after insertion if deviating from the recommended timing of insertion. If intercourse has already occurred, pregnancy should be excluded.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<sup>b</sup> COC = Combined oral contraceptive</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<sup>c</sup> IUS = intrauterine system</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">COC<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel on the day after the last active tablet was taken. At the latest, insert on the day following the usual tablet-free or placebo interval.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Progestin-only implant</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel on same day as removal of implant.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Progestin-only injection</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel on day next injection is due.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Progestin-only IUS<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel on same day as removal of IUS.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Progestin-only pill</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel any day during the month within 24 hours of taking the last tablet.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Transdermal patch</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel on the day when the transdermal patch is removed. At the latest, insert on the day following the transdermal-free interval.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Vaginal ring</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel on the day the vaginal ring is removed. At the latest, insert on the day following the ring-free interval.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Use after childbirth (breastfeeding)</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel after the fourth postpartum week and use a barrier method of contraception for the first 7 days of insertion. If intercourse has already occurred, pregnancy should be excluded.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Use after childbirth (not breastfeeding)</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel between 21 to 28 days postpartum.<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Use after first trimester abortion or miscarriage</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel within first 5 days following first trimester abortion or miscarriage.<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Use after second trimester abortion or miscarriage</p></td>
<td align="center">
<p style="text-indent:0em;">Insert etonogestrel between 21 and 28 days following second trimester abortion or miscarriage.<sup>a</sup></p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990163"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987499"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block dop drugH1Div" id="F3325911"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="127394" href="/d/html/127394.html" rel="external">see "Etonogestrel implant: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception:</b> Postmenarche females: Subdermal: Insert 1 implant in the inner side of the upper, nondominant arm. Remove no later than 3 years after the date of insertion; may be replaced with a new implant at the time of removal if continued contraceptive protection is desired. After ruling out pregnancy, timing of insertion is based on the patient's recent contraceptive history:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>No hormonal contraceptives within the past month:</i> Insert between days 1 through 5 of menstruation, even if woman is still bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from combination hormonal contraceptive:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Oral tablet: Insert on the day after the last active tablet (at the latest, insert on the day following the usual tablet-free or placebo interval).</p>
<p style="text-indent:-2em;margin-left:6em;">Transdermal system or vaginal ring: Insert on the day of the removal of the transdermal system or vaginal ring (at the latest, insert on the day following the transdermal-free or ring-free interval).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from a progestin-only contraceptive:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Oral tablet: Any day during the month; do not skip days between the last tablet and implant insertion.</p>
<p style="text-indent:-2em;margin-left:6em;">Implant or intrauterine device (IUD): Insert on same day as removal of implant or IUD.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection: Insert on day next injection is due.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>First trimester abortion or miscarriage:</i> Insert within first 5 days following first trimester abortion or miscarriage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Second trimester abortion or miscarriage:</i> Insert between 21 and 28 days following second trimester abortion or miscarriage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postpartum:</i> If not breastfeeding, insert between 21 to 28 days postpartum. If breastfeeding, insert after the fourth postpartum week and use a second nonhormonal form of contraception for the first 7 days of insertion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If following any of the above insertion schedules, no back-up contraception needed (except in postpartum women who are breastfeeding). If deviating, use a back-up nonhormonal contraceptive method for 7 days postinsertion. If intercourse has already occurred, pregnancy should be excluded.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional dosing considerations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initiation of therapy: May be started at any time in the menstrual cycle once it is determined that the woman is not pregnant. Back-up contraception is not needed if started within 5 days of onset of menstruation. If started &gt;5 days after the onset of menstruation or at any time in a woman experiencing amenorrhea (not postpartum), back-up contraception should be used for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Switching from a different contraceptive to an implant: May be started at any time if it is determined that the woman is not pregnant. Unless the woman abstains from sexual intercourse, a back-up method of contraception is needed if it has been &gt;5 days since menstrual bleeding has begun. When an additional method of contraception is needed, consider continuing the woman's previous method for 7 days after inserting the implant.</p>
<p style="text-indent:-2em;margin-left:4em;">Switching from an IUD to an implant: Continue the IUD for ≥7 days after the implant is inserted or advise the woman to abstain from sexual intercourse or use a barrier contraceptive for 7 days before removing the IUD. Alternately, an emergency contraceptive may be used at the time of IUD removal.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109927"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51109928"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F57147246"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Gynecological bleeding</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Etonogestrel is associated with changes in<b> gynecological bleeding </b>patterns (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24329119','lexi-content-ref-31958877','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24329119','lexi-content-ref-31958877','lexi-content-ref-29386936'])">Ref</a></span>). Reported bleeding patterns include infrequent, absent, prolonged, and frequent bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-31958877','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-31958877','lexi-content-ref-29386936'])">Ref</a></span>). While bleeding irregularities may affect quality of life, they are generally not harmful (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-31958877','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-31958877','lexi-content-ref-29386936'])">Ref</a></span>). However, they are the most common reason for discontinuation among users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24329119','lexi-content-ref-31958877','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24329119','lexi-content-ref-31958877','lexi-content-ref-29386936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; hypotheses include estrogen changes and changes in molecular and/or cellular mechanisms within the endometrium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24329119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24329119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; changes in bleeding patterns during the first 3 months of therapy may be predictive of continued bleeding irregularities throughout therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24329119','lexi-content-ref-31958877','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24329119','lexi-content-ref-31958877','lexi-content-ref-29386936'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F3325853"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Gynecological bleeding (including amenorrhea [22%], frequent bleeding [7%], heavy menstrual bleeding, infrequent uterine bleeding [34%], prolonged menstrual bleeding [18%], spotty menstruation [12% to 37%]), mastalgia (13%), vaginitis (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (7%), leukorrhea (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (implant site: 9%; including bruise [2%], hematoma [3%], localized erythema [3%], local pain [1% to 5%], local swelling [&lt;1%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (6%), dizziness (7%), emotional lability (7%), nervousness (6%), pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (postmenarche females and adults):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, deep vein thrombosis, edema, increased blood pressure, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Lee 2006), chloasma, hypertrichosis, pruritus, seborrhea, skin rash, toxic epidermal necrolysis (Amin 2022), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, hot flash, porphyria (cutaneous variegate) (Strome 2022), weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, diarrhea, flatulence, increased appetite, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy, dysuria, ectopic pregnancy (Rodrigues 2021), genital pruritus, nipple discharge, ovarian cyst, urinary tract infection, vaginal discomfort</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (including exacerbation of angioedema and exacerbation of hereditary angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, cerebrovascular accident, drowsiness, fatigue, insomnia, intracranial hypertension (Tan 2019), migraine, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lipoatrophy (application site) (Lindsay 2009), musculoskeletal pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F3325848"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to etonogestrel or any component of the formulation; breast cancer (known, suspected, or personal history of); progestin-sensitive cancer (current or a history of); hepatic tumors (benign or malignant) or active hepatic disease; pregnancy (known or suspected); thrombosis or thromboembolic disorders (current or history of); undiagnosed abnormal genital bleeding.</p></div>
<div class="block war drugH1Div" id="F3325849"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cervical cancer: The use of combination hormonal contraceptives has been associated with a slight increased risk of cervical cancer; however, studies are not consistent, and the risk may be related to the specific histologic type of cervical cancer, duration of contraceptive use, and other factors (Asthana 2020; Gadducci 2020). Theoretically, use may affect prognosis of existing disease. Patients awaiting treatment for cervical cancer may use progestin-only contraceptives (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cysts: Follicular development may occur and may continue to increase in size beyond what may occur in a normal cycle; generally, ovarian cysts resolve spontaneously without intervention; however, surgery may rarely be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal thrombosis: Discontinue if unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions occur and immediately evaluate for retinal thrombosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Combination hormonal contraceptives may increase the risk of vascular and deep venous thrombotic events (eg, deep vein thrombosis [DVT], myocardial infarction, pulmonary embolism [PE], retinal vein thrombosis, stroke, venous thromboembolism [VTE]). The risk of DVT/PE is expected to be less with progestin only contraceptives than that observed with combination hormonal contraceptives (CDC [Curtis 2016b]). Use caution in patients with risk factors for thromboembolism; remove implant if an arterial or venous thromboembolic event occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight gain: Use commonly results in an average weight gain of ~2.8 pounds after 1 year and ~3.7 pounds after 2 years of treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Fertility is increased following bariatric surgery. All available forms of contraception can be considered following bariatric surgery, considering the patient's body weight and time since surgery; however, long-acting reversible nonoral contraceptives (eg, implants, IUDs) may be preferred. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy both have the potential to expedite transit through the small bowel. RYGB may not significantly alter the absorption of oral estrogen or progestins (limited evidence following a single dose); however, gastric and small bowel transit is not well studied following chronic oral dosing, therefore contraceptive efficacy cannot be guaranteed. Oral contraceptives may be used in patients having adjustable gastric banding unless there is diarrhea or vomiting. Reliable contraception using oral contraceptives cannot be guaranteed following jejunoileal bypass, biliopancreatic diversion, single anastomosis duodeno-ilial bypass, or omega-loop gastric bypass. Estrogen-containing birth control should be stopped at least 4 weeks prior to bariatric surgery and resumed no earlier than 4 weeks after surgery to minimize risk of VTE (Ciangura 2019; Mechanick 2020; Moreira de Brito 2021; Shawe 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with risk factors for cardiovascular disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, patients who smoke) (CDC [Curtis 2016b])</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with a history of depression; consider removing implant if serious depression occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May impair glucose tolerance; use caution in patients with diabetes or prediabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Use of combination hormonal contraceptives may have an increased risk of developing gallbladder disease; it is not known if this risk increases with progestin only products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic adenomas or carcinomas: Use of combination hormonal contraceptives is associated with hepatic adenomas (rare). The risk with progestin only contraceptives is not known.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Etonogestrel may be poorly metabolized in patients with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Use caution in patients treated for hyperlipidemia; progestins may increase low-density lipoprotein concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: According to the manufacturer, patients with a history of hypertension-related diseases should be encouraged to use a nonhormonal form of contraception. In patients with hypertension that is well-controlled, use may be considered; monitor BP closely. If sustained hypertension develops during use, or if a significant increase in BP does not respond adequately to antihypertensive therapy, remove the implant. Patients with adequately controlled hypertension may use progestin-only implants; other risk factors for cardiovascular disease (such as older age, smoking, diabetes) should be considered when prescribing (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Patients with renal disease should be encouraged to use a nonhormonal form of contraception.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: Lower etonogestrel serum concentrations are associated with increased BMI (Lazorwitz 2019). Use with caution in patients who are overweight (may be less effective, especially in the presence of other risk factors such as concomitant enzyme inducers that may influence serum concentrations). Women &gt;130% of ideal body weight were not included in clinical studies; however, contraceptive failure was not observed in patients who were obese in a prospective study (Xu 2012). Progestin-only implants may be used in patients with a BMI ≥30 kg/m<sup>2</sup> (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Any changes with lens tolerance or vision should be evaluated by an ophthalmologist.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Consider removal during periods of prolonged immobilization due to surgery or illness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Implant: Broken or bent implants while in the patient's arm have been reported (may be related to manipulation of the implant or contact sports); migration of broken implant fragments within the arm have also been reported. The release rate of etonogestrel may be slightly increased with broken or bent implants. Ensure implant is removed in its entirety.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Improper insertion may lead to unintended pregnancy. Insertion/removal should be done by a trained health care provider and implant must be palpable after insertion. Complications may occur from insertion and removal procedures including bleeding, hematoma, infection, pain, scarring, paraesthesia (due to neural injury), migration of the implant (due to IM or fascial insertion), and intravascular insertion. Cases in which the implant migrated within the pulmonary artery have been asymptomatic or associated with chest pain and/or respiratory disorders (eg, cough, dyspnea, hemoptysis). Deeply placed implants (deeper than subdermally) should be localized and removed as soon as possible to prevent migration. Treatment should be instituted for infection at the insertion site; if infection persists, the implant should be removed. Expulsion may occur following incomplete insertion or infection. The implant must be removed by the end of the third year.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV infection protection: Use does not protect against HIV infection or other sexually transmitted diseases (CDC [Curtis 2016a]; CDC [Curtis 2016b]).</p></div>
<div class="block foc drugH1Div" id="F3325924"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexplanon: 68 mg (1 ea) [latex free]</p></div>
<div class="block geq drugH1Div" id="F3325517"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322952"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Nexplanon Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">68 mg (per each): $1,387.54</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54870319"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexplanon: 68 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F3325916"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Subdermal:</b> For subdermal insertion by health care providers trained in the insertion and removal procedure. Insert implant subdermally just under the skin at the inner side of the nondominant upper arm overlying the triceps muscle ~8 to 10 cm (3 to 4 inches) from the medial epicondyle of the humerus and 3 to 5 cm (1.25 to 2 inches) posterior to the sulcus between the biceps and triceps muscles. This location is intended to avoid the large blood vessels and nerves lying within and surrounding the sulcus. If it is not possible to insert at this location (eg, in patients with thin arms), insert as far posterior from the sulcus as possible. To ensure proper placement just under the skin, view advancement of the needle from the side, not from above the patient. Implant must be palpable after insertion. X-ray, CT scan, ultrasound scanning, or MRI may also be used to confirm the location of the implant if it is not palpable. Deeply placed implants (deeper than subdermally) should be localized and removed as soon as possible. Removal of deeply placed implants, implants that are not palpable, or implants that cannot be grasped during removal should be performed by health care providers trained in complex removal procedures. Inspect packaging prior to use; do not use if damaged (eg, torn, punctured). Use of a nonhormonal contraceptive (eg, condom) is required until the presence of the implant can be verified.</p>
<p style="text-indent:-2em;margin-left:2em;">Perform removal under aseptic conditions. Inject local anesthetic under (not over) the implant. Confirm that the entire implant has been removed by measuring its length (4 cm). Remove all pieces if implant has broken. A new implant may be inserted in the same arm through the same incision as long as the site is in the correct location.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to the manufacturer's product labeling for complete insertion, removal, and reinsertion instructions. Materials related to the insertion and removal of etonogestrel implant (including videos demonstrating insertion and removal) are available from the manufacturer (1-844-674-3200); www.nexplanontraining.com.</p></div>
<div class="block admp drugH1Div" id="F52614144"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Subdermal: For insertion under local anesthesia by health care providers trained in the insertion and removal procedure. Insert implant subdermally just under the skin at the inner side of the nondominant arm overlying the triceps muscle ~8 to 10 cm (3 to 4 inches) from the medial epicondyle of the humerus and 3 to 5 cm (1.25 to 2 inches) posterior to the sulcus between the biceps and triceps muscles. To ensure proper placement just under the skin, view advancement of the needle from the side, not from above the patient. Implant must be palpable after insertion. X-ray, CT scan, ultrasound scanning, or MRI may also be used to confirm the location of the implant if it is not palpable. Deeply-placed implants should be localized and removed as soon as possible. Removal of deeply-placed implants, implants that are not palpable, or implants that cannot be grasped during removal should be performed by health care providers trained in complex removal procedures. Use of a nonhormonal contraceptive (eg, condom) is required until the presence of the implant can be verified.</p>
<p style="text-indent:-2em;margin-left:2em;">Perform removal under aseptic conditions. Inject local anesthetic under (not over) the implant. When removing the implant, confirm that the entire implant has been removed by measuring its length (4 cm). Remove all pieces if implant has broken. A new implant may be inserted in the same arm through the same incision as long as the site is in the correct location.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to the manufacturer's product labeling for complete insertion, removal, and reinsertion instructions. A User Card (to give to the patient), consent form (to keep on file), and patient product information are provided with the device. Materials related to the insertion and removal of etonogestrel implant (including videos demonstrating insertion and removal) are available from the manufacturer.</p></div>
<div class="block hazard drugH1Div" id="F49132452"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]). </p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving and a protective gown during administration (NIOSH 2016).</p></div>
<div class="block use drugH1Div" id="F3325523"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception:</b> For the prevention of pregnancy</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Limitations of use:</i> For use in patients who may become pregnant; not for use prior to menarche or post menopause.</p></div>
<div class="block off-label drugH1Div" id="F56304722"><span class="drugH1">Use: Off-Label: Adult</span><p>Dysmenorrhea (primary and secondary to endometriosis)</p></div>
<div class="block mst drugH1Div" id="F56381685"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F3325862"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F3325861"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with aprepitant, and to continue back-up contraception for 28 days after discontinuing aprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asparaginase Products: Hormonal Contraceptives may enhance the thrombogenic effect of Asparaginase Products.  Management: Consider discontinuing hormonal contraceptives and using an alternative contraceptive method in patients treated with asparaginase products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May decrease the serum concentration of Hormonal Contraceptives. Management: Use of a high-dose oral contraceptive (at least 30 mcg of ethinyl estradiol combined with norethindrone) is recommended when combined with asunaprevir. Consider an additional barrier method when other forms of contraception are used with asunaprevir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, atazanavir/ritonavir may decrease concentrations of estrogens. Atazanavir may increase the serum concentration of Hormonal Contraceptives. Specifically, atazanavir alone may increase concentrations of estrogens and atazanavir alone or boosted may increase concentrations of progestins. Management: Dose adjustment of hormonal contraceptives or use of alternative or additional nonhormonal contraceptive may be needed when combined with atazanavir. See full interact monograph for details. Atazanavir/cobicistat with drospirenone is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a non-hormonal contraceptive during brigatinib use and for at least 4 months after the last brigatinib dose. Males with partners of reproductive potential should use contraception during treatment with brigatinib and for 3 months after brigatinib use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carfilzomib: Hormonal Contraceptives may enhance the thrombogenic effect of Carfilzomib.  Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib, especially patients using carfilzomib in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May decrease the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may decrease serum concentrations of estrogens. Cobicistat may increase the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may increase serum concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with cobicistat. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the adverse/toxic effect of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a back-up method during coadministration, and to continue back-up contraception for 12 weeks after stopping efavirenz to ensure contraceptive reliability. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: Hormonal Contraceptives may diminish the therapeutic effect of Elagolix. Specifically, estrogen-containing hormonal contraceptives may diminish the therapeutic effects of elagolix. Elagolix may decrease the serum concentration of Hormonal Contraceptives. Specifically, concentrations of progestins may be decreased with elagolix therapy. Elagolix may increase the serum concentration of Hormonal Contraceptives. Specifically, concentrations of ethinyl estradiol may be increased with elagolix therapy.  Management: Use an alternative, nonhormonal contraceptive during treatment with elagolix and for at least 28 days following discontinuation of elagolix treatment. Use of elagolix 200 mg twice daily with an estrogen-containing hormonal contraceptive is not recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: Hormonal Contraceptives may enhance the adverse/toxic effect of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the risk for rash may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Hormonal Contraceptives. Specifically, progestin concentrations may decrease. Etravirine may increase the serum concentration of Hormonal Contraceptives. Specifically, estrogen concentrations may increase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exenatide: Hormonal Contraceptives may diminish the therapeutic effect of Exenatide. Exenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives at least one hour prior to exenatide. Monitor blood glucose more frequently when patients treated with exenatide initiate therapy with a hormonal contraceptive. Increases in exenatide doses may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing felbamate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: Hormonal Contraceptives may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with fosaprepitant, and to continue back-up contraception for 28 days after discontinuing fosaprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing griseofulvin to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May decrease the serum concentration of Hormonal Contraceptives. Management: Consider alternative methods of contraception (ie, non-hormonal) in patients receiving ivosidenib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: May decrease the serum concentration of Hormonal Contraceptives. More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of hormonal contraceptives. Management: Patients of reproductive potential should use a non-hormonal contraceptive method during treatment with ixazomib and for at least 90 days after the last ixazomib dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lixisenatide: Hormonal Contraceptives may diminish the therapeutic effect of Lixisenatide. Lixisenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives 1 hour before or at least 11 hours after administration of lixisenatide. Additionally, monitor blood glucose more frequently when patients treated with lixisenatide initiate therapy with a hormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative contraceptive that is not sensitive to CYP3A4 induction or a back-up method during coadministration, and to continue back-up contraception for 4 months after stopping mavacamten to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Nonhormonal contraception should be used during, and for 4 weeks following, mifepristone treatment for hyperglycemia due to Cushing syndrome. If used for pregnancy termination, hormonal contraceptives can be used after pregnancy expulsion is confirmed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitotane: May decrease the serum concentration of Hormonal Contraceptives. Management: Effective nonhormonal contraception is recommended for those of reproductive potential during treatment with mitotane as well as after discontinuation of mitotane for as long as mitotane plasma levels are detectable.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients of childbearing potential who are taking hormonal contraceptives should use an additional form of barrier contraception during treatment with mycophenolate and for 6 weeks after mycophenolate discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may decrease concentrations of estrogens. Nirmatrelvir and Ritonavir may increase the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may increase concentrations of progestins. Management: Use additional nonhormonal forms of contraception (back-up method) when estrogen-containing hormonal contraceptives are combined with nirmatrelvir/ritonavir. Progestin-only contraceptives can be used without back-up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: May decrease the serum concentration of Hormonal Contraceptives. Management: Women should use an alternative non-hormonal method of contraception or a back-up method when octreotide is combined with hormonal contraceptives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Avoid use of olutasidenib with sensitive or narrow therapeutic index CYP3A4 substrates when possible. If concurrent use with olutasidenib is unavoidable, monitor closely for evidence of decreased concentrations of the CYP3A4 substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing oxcarbazepine to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients should use an alternative, nonhormonal-based form of contraception during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with pitolisant and for at least 21 days after discontinuation of pitolisant treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may decrease concentrations of estrogens. Protease Inhibitors may increase the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may increase concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with protease inhibitors. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: May decrease the serum concentration of Hormonal Contraceptives. Management: Individuals of childbearing potential should use a non-hormonal contraceptive method during treatment with tazemetostat and for 6 months after. Males with partners of childbearing potential should use contraception during treatment and for 3 months after.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: May decrease the serum concentration of Hormonal Contraceptives. Management: Product labeling recommends that patients taking hormonal contraceptives should use an additional, non-hormonal contraceptive or reliable barrier method during treatment with tetrahydrocannabinol and cannabidiol buccal spray.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Hormonal Contraceptives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation of tirzepatide and for 4 weeks after each dose escalation of tirzepatide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing topiramate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Hormonal Contraceptives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing meropenem/vaborbactam to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Hormonal Contraceptives may increase the serum concentration of Vitamin K Antagonists. Hormonal Contraceptives may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Hormonal Contraceptives may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54124394"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use.</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risk of thromboembolism associated with pregnancy and the immediate postpartum period, the manufacturer does not recommend insertion &lt;21 days' postpartum; however, available guidelines state that progestin-only implants may be inserted at any time if it is reasonably certain the patient is not pregnant, including immediately postpartum or post abortion (CDC [Curtis 2016a]). Administration immediately postpartum (prior to hospital discharge) may be offered regardless of breastfeeding status and may help prevent rapid repeat and unintended pregnancies (ACOG 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Etonogestrel serum concentrations decrease by 1 week after removal of the implant; pregnancies have been reported as early as 7 to 14 days after removal. Restart contraception immediately after removal if continued contraception is desired.</p>
<p style="text-indent:0em;margin-top:2em;">All available forms of contraception, including etonogestrel, can be considered for patients on gender-affirming testosterone therapy after evaluating patient preferences and medical conditions (eg, risk for venous thromboembolism). Amenorrhea may be induced more rapidly when the implant is initiated with testosterone therapy (Bonnington 2020; Krempasky 2020).</p></div>
<div class="block pri drugH1Div" id="F3325524"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Etonogestrel is used to prevent pregnancy; the implant should be removed if pregnancy occurs. In general, the use of combination hormonal contraceptives, when inadvertently used early in pregnancy, have not been associated with teratogenic effects. There is no evidence that the risk is different with etonogestrel.</p>
<p style="text-indent:0em;margin-top:2em;">Ectopic pregnancy (rare) may occur more commonly than in patients using no contraception. The possibility of ectopic pregnancy should be considered in patients with lower abdominal pain.</p></div>
<div class="block brc drugH1Div" id="F3325847"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Etonogestrel is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of etonogestrel in breast milk is available from 42 breastfeeding patients who initiated treatment 4 to 8 weeks postpartum. In a 4-month study, milk concentrations were highest 1 month after insertion of the implant and decreased as the dose released from the implant and maternal serum concentrations decreased (Reinprayoon 2000). The manufacturer reports the relative infant dose (RID) of etonogestrel to be 2.2% of the weight-adjusted maternal dose. In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">There are theoretical concerns that progestin implants may prevent the onset of lactogenesis (ACOG 2016); however, etonogestrel was not found to affect the quality or quantity of breast milk (Reinprayoon 2000). Breastfed infants of mothers with an etonogestrel implant were not found to have differences in growth (body length, biparietal head circumference, body weight) or adverse physical or psychomotor development in comparison to those infants of mothers using a nonhormonal contraceptive IUD (mean duration of breastfeeding was 421 days); infants were evaluated over 36 months (Taneepanichskul 2006). No difference in infant growth at 12 months of age was found with implant insertion within 48 hours of delivery compared to insertion 6 weeks after delivery; the majority of women in the study exclusively breastfed for 40 to 90 days postpartum (Carmo 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of use to the mother. Although the manufacturer does not recommend insertion of the implant prior to 4 weeks postpartum, guidelines affirm progestin-only implants may be inserted at any time if it is reasonably certain the woman is not pregnant, including immediately postpartum in breastfeeding women (CDC [Curtis 2016a]).</p></div>
<div class="block mop drugH1Div" id="F3325920"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Assessment of pregnancy status (prior to therapy); weight (optional; body mass index [BMI] at baseline may be helpful to monitor changes during therapy); assess potential health status changes at routine visits (CDC [Curtis 2016a]).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patient for vision changes; BP; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with prediabetes or diabetes; lipid profiles in patients being treated for hyperlipidemias. Bleeding irregularities including amenorrhea; adequate diagnostic measures should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.</p></div>
<div class="block pha drugH1Div" id="F3325923"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Etonogestrel is the active metabolite of desogestrel. It prevents pregnancy by suppressing ovulation, increasing the viscosity of cervical mucous, and inhibiting endometrial proliferation. </p></div>
<div class="block phk drugH1Div" id="F3325868"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Each implant maintains etonogestrel levels sufficient to inhibit ovulation for 3 years</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~201 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Albumin (66%) and sex hormone-binding globulin (~32%)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4; forms metabolites (activity not known)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Implant: 100%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: ~25 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily); feces</p>
<p style="text-indent:-2em;margin-left:2em;">Pharmacokinetics note: The rod releases etonogestrel at a rate of 60 to 70 mcg/day in week 5 to 6, decreasing to ~35 to 45 mcg/day at the end of the first year, ~30 to 40 mcg/day at the end of the second year, and ~25 to 30 mcg/day at the end of the third year. Following removal of rod, levels decrease rapidly and are less than the level of detection within 1 week</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539978"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt | Nexplanon</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Nexplanon</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Nexplanon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nexplanon</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Nexplanon</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Nexplanon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Implanon NXT</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nexplanon</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Etoplan | Implanon | Implanon nxt</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Nexplanon</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Implanon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Implanon nxt</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27454734">
<a name="27454734"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 670: immediate postpartum long-acting reversible contraception. <i>Obstet Gynecol</i>. 2016;128(2):e32-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/27454734/pubmed" id="27454734" target="_blank">27454734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29064972">
<a name="29064972"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice bulletin no. 186: long-acting reversible contraception: implants and intrauterine devices. <i>Obstet Gynecol</i>. 2017;130(5):e251-e269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/29064972/pubmed" id="29064972" target="_blank">29064972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461694">
<a name="30461694"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 760: dysmenorrhea and endometriosis in the adolescent. <i>Obstet</i>
<i>Gynecol</i>. 2018;132(6):e249-e258. doi:10.1097/AOG.0000000000002978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/30461694/pubmed" id="30461694" target="_blank">30461694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35815235">
<a name="35815235"></a>Amin M, Liao CD, Simpson RL. Toxic epidermal necrolysis caused by etonogestrel implantation: a rare presentation. <i>JAAD Case Rep</i>. 2022;26:6-8. doi:10.1016/j.jdcr.2022.05.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/35815235/pubmed" id="35815235" target="_blank">35815235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32114321">
<a name="32114321"></a>Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer - a systematic review &amp; meta-analysis. <i>Eur J Obstet Gynecol Reprod</i>
<i>Biol</i>. 2020;247:163-175. doi:10.1016/j.ejogrb.2020.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/32114321/pubmed" id="32114321" target="_blank">32114321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32304766">
<a name="32304766"></a>Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. <i>Contraception</i>. 2020;102(2):70-82. doi:10.1016/j.contraception.2020.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/32304766/pubmed" id="32304766" target="_blank">32304766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28594758">
<a name="28594758"></a>Carmo LSMP, Braga GC, Ferriani RA, Quintana SM, Vieira CS. Timing of etonogestrel-releasing implants and growth of breastfed infants: a randomized controlled trial. <i>Obstet Gynecol</i>. 2017;130(1):100-107. doi:10.1097/AOG.0000000000002092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/28594758/pubmed" id="28594758" target="_blank">28594758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). US selected practice recommendations for contraceptive use, 2016: implants. <a href="https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/implants.html" target="_blank">https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/implants.html</a>. Updated February 1, 2017. Accessed May 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606136">
<a name="31606136"></a>Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review. <i>Fertil Steril</i>. 2019;112(6):1034-1042. doi:10.1016/j.fertnstert.2019.07.1349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31606136/pubmed" id="31606136" target="_blank">31606136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31493139">
<a name="31493139"></a>Ciangura C, Coupaye M, Deruelle P, et al; BARIA-MAT Group. Clinical practice guidelines for childbearing female candidates for bariatric surgery, pregnancy, and post-partum management after bariatric surgery. <i>Obes Surg</i>. 2019;29(11):3722-3734. doi:10.1007/s11695-019-04093-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31493139/pubmed" id="31493139" target="_blank">31493139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467319">
<a name="27467319"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1‐66. doi: 10.15585/mmwr.rr6504a1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/27467319/pubmed" id="27467319" target="_blank">27467319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467196">
<a name="27467196"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1‐103. doi: 10.15585/mmwr.rr6503a1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/27467196/pubmed" id="27467196" target="_blank">27467196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33109537">
<a name="33109537"></a>Gadducci A, Cosio S, Fruzzetti F. Estro-progestin contraceptives and risk of cervical cancer: a debated issue. <i>Anticancer Res</i>. 2020;40(11):5995-6002. doi:10.21873/anticanres.14620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/33109537/pubmed" id="33109537" target="_blank">33109537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31394072">
<a name="31394072"></a>Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum.<i> Am J Obstet Gynecol</i>. 2020;222(2):134-143. doi:10.1016/j.ajog.2019.07.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31394072/pubmed" id="31394072" target="_blank">31394072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30980827">
<a name="30980827"></a>Lazorwitz A, Aquilante CL, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. <i>Contraception</i>. 2019;100(1):37-41. doi:10.1016/j.contraception.2019.03.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/30980827/pubmed" id="30980827" target="_blank">30980827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17032520">
<a name="17032520"></a>Lee DJ, Ewer K. Implanon and alopecia. <i>J Fam Plann Reprod Health Care</i>. 2006;32(4):255. doi:10.1783/147118906778586435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/17032520/pubmed" id="17032520" target="_blank">17032520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19849933">
<a name="19849933"></a>Lindsay P. Localised lipoatrophy at the site of Implanon insertion. <i>J Fam Plann Reprod Health Care</i>. 2009;35(4):266. doi:10.1783/147118909789587178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/19849933/pubmed" id="19849933" target="_blank">19849933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg</i>
<i>Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33547015">
<a name="33547015"></a>Moreira de Brito C, de Melo ME, Mancini MC, Santo MA, Cercato C. Pharmacokinetics of oral levonorgestrel and ethinyl estradiol in women after Roux-en-Y gastric bypass surgery. <i>Surg Obes Relat Dis</i>. 2021;17(4):673-681. doi:10.1016/j.soard.2020.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/33547015/pubmed" id="33547015" target="_blank">33547015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexplanon.1">
<a name="Nexplanon.1"></a>Nexplanon (etonogestrel) [prescribing information]. Jersey City, NJ: Organon USA LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11172794">
<a name="11172794"></a>Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device). <i>Contraception</i>. 2000;62(5):239-246. doi:10.1016/s0010-7824(00)00173-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/11172794/pubmed" id="11172794" target="_blank">11172794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34785516">
<a name="34785516"></a>Rodrigues ML, Branco R, Landim E. Ectopic pregnancy with etonogestrel implant. <i>BMJ Case Rep.</i> 2021;14(11):e245175. doi:10.1136/bcr-2021-245175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/34785516/pubmed" id="34785516" target="_blank">34785516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31419378">
<a name="31419378"></a>Shawe J, Ceulemans D, Akhter Z, et al. Pregnancy after bariatric surgery: consensus recommendations for periconception, antenatal and postnatal care. <i>Obes Rev</i>. 2019;20(11):1507-1522. doi:10.1111/obr.12927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31419378/pubmed" id="31419378" target="_blank">31419378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538049">
<a name="21538049"></a>Sitruk-Ware R and Nath A, "Metabolic Effects of Contraceptive Steroids," <i>Rev Endocr Metab Disord</i>, 2011, 12(2):63-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/21538049/pubmed" id="21538049" target="_blank">21538049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35360373">
<a name="35360373"></a>Strome A, Hawkins SD, Huang YY, Helfrich YR. A case report on variegate porphyria after etonogestrel placement. <i>JAAD Case Rep</i>. 2022;22:104-106. doi:10.1016/j.jdcr.2022.02.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/35360373/pubmed" id="35360373" target="_blank">35360373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes [published online November 18, 2019]. <i>Am J Clin Dermatol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16531169">
<a name="16531169"></a>Taneepanichskul S, Reinprayoon D, Thaithumyanon P, Praisuwanna P, Tosukhowong P, Dieben T. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. <i>Contraception</i>. 2006;73(4):368-371.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/16531169/pubmed" id="16531169" target="_blank">16531169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24329119">
<a name="24329119"></a>Teunissen AM, Grimm B, Roumen FJ. Continuation rates of the subdermal contraceptive Implanon(®) and associated influencing factors. <i>Eur J Contracept Reprod Health Care</i>. 2014;19(1):15-21. doi:10.3109/13625187.2013.862231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/24329119/pubmed" id="24329119" target="_blank">24329119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31958877">
<a name="31958877"></a>Upawi SN, Ahmad MF, Abu MA, Ahmad S. Management of bleeding irregularities among etonogestrel implant users: Is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option?. <i>J Obstet Gynaecol Res</i>. 2020;46(3):479-484. doi:10.1111/jog.14195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/31958877/pubmed" id="31958877" target="_blank">31958877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29386936">
<a name="29386936"></a>Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. <i>Open Access J Contracept</i>. 2016;7:43-52. doi:10.2147/OAJC.S85565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/29386936/pubmed" id="29386936" target="_blank">29386936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22678035">
<a name="22678035"></a>Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. <i>Obstet Gynecol</i>. 2012;120(1):21-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etonogestrel-implant-drug-information/abstract-text/22678035/pubmed" id="22678035" target="_blank">22678035</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8870 Version 305.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
